Idorsia initiates pivotal Phase 3 study for lucerastat in Fabry disease and enters co-development and commercialization agreement with Nxera
Globe Newswirevia NewsData.io
Idorsia initiates Phase 3 study with lucerastat in patients with Fabry disease, and enters co-development and commercialization agreement with Nxera.
Headline and summary provided via NewsData.io. The full article and its copyright belong to the original publisher.